Bio-Rad Laboratories, Inc.
BIO · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $9,268,581 | $9,431,294 | $12,524,295 | $22,539,409 |
| - Cash | $488,100 | $403,800 | $434,215 | $470,783 |
| + Debt | $1,374,700 | $1,405,500 | $1,388,098 | $223,376 |
| Enterprise Value | $10,155,181 | $10,432,994 | $13,478,178 | $22,292,002 |
| Revenue | $2,566,500 | $2,671,262 | $2,802,249 | $2,922,545 |
| % Growth | -3.9% | -4.7% | -4.1% | – |
| Gross Profit | $1,378,900 | $1,426,946 | $1,567,330 | $1,638,096 |
| % Margin | 53.7% | 53.4% | 55.9% | 56.1% |
| EBITDA | -$2,142,000 | -$654,800 | -$4,488,959 | $5,588,206 |
| % Margin | -83.5% | -24.5% | -160.2% | 191.2% |
| Net Income | -$1,844,200 | -$637,324 | -$3,627,535 | $4,254,257 |
| % Margin | -71.9% | -23.9% | -129.5% | 145.6% |
| EPS Diluted | -65.36 | -21.82 | -121.79 | 140.83 |
| % Growth | -199.5% | 82.1% | -186.5% | – |
| Operating Cash Flow | $455,200 | $374,943 | $194,447 | $669,464 |
| Capital Expenditures | -$189,000 | -$156,680 | -$114,157 | -$133,746 |
| Free Cash Flow | $266,200 | $218,263 | $80,290 | $535,718 |